Bryan M. Reasons

Insider Reports History

Location
Hayward, CA
Signature
/s/ Mark Tyndall, Attorney-in-Fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Bryan M. Reasons:

Company Role Class Num Shares Value Price $ Report Date Ownership
Aclaris Therapeutics, Inc. Director Common Stock 28,732 $36,202 $1.26 01 Jun 2024 Direct
Aclaris Therapeutics, Inc. Director Restricted Stock Units 0 $0 $1.26 01 Jun 2024 Direct
Societal CDMO, Inc. Director Common Stock 0 $0 $1.10 08 Apr 2024 Direct
Mallinckrodt plc EVP & CFO Restricted Stock Units 54,714 31 Jul 2025 Direct
Aclaris Therapeutics, Inc. Director Stock Option (Right to Buy) 15,750 01 Jun 2023 Direct
Mallinckrodt plc EVP & CFO Ordinary Shares 5,114 $37.50 01 Jan 2025 Direct
Societal CDMO, Inc. Director Stock Option (Right to Buy) 0 08 Apr 2024 Direct

Insider Reports Filed by Bryan M. Reasons

Symbol Company Period Transactions Value $ Form Type Role Filing Time
/report/000110465925073784-reasons-bryan-m-2025-07-31 Mallinckrodt plc 31 Jul 2025 1 $0 4 EVP & CFO 04 Aug 2025, 20:47
/report/000110465925000368-reasons-bryan-m-2025-01-01 Mallinckrodt plc 01 Jan 2025 3 $0 4 EVP & CFO 02 Jan 2025, 17:01
ACRS Aclaris Therapeutics, Inc. 01 Jun 2024 2 $0 4 Director 04 Jun 2024, 16:30
/report/000110465924044896-reasons-bryan-m-2024-04-08 Societal CDMO, Inc. 08 Apr 2024 4 -$320,154 4 Director 08 Apr 2024, 21:34
/report/000110465924011128-reasons-bryan-m-2024-02-02 Mallinckrodt plc 02 Feb 2024 1 $0 4 EVP & CFO 06 Feb 2024, 16:31
/report/000110465923119124-reasons-bryan-m-2023-11-14 Mallinckrodt plc 14 Nov 2023 1 $0 4 EVP & CFO 16 Nov 2023, 16:15
/report/000106299323017166-reasons-bryan-m-2023-08-28 Societal CDMO, Inc. 28 Aug 2023 1 +$25,000 4 Director 28 Aug 2023, 16:32
/report/000110465923093621-reasons-bryan-m-2023-08-17 Mallinckrodt plc 17 Aug 2023 1 -$11,071 4 EVP & CFO 18 Aug 2023, 21:21
/report/000110465923078291-reasons-bryan-m-2023-06-30 Mallinckrodt plc 30 Jun 2023 1 $0 4 EVP & CFO 05 Jul 2023, 18:16
ACRS Aclaris Therapeutics, Inc. 01 Jun 2023 4 $0 4 Director 05 Jun 2023, 16:57
/report/000106299323011843-reasons-bryan-m-2023-05-17 Societal CDMO, Inc. 17 May 2023 2 $0 4 Director 19 May 2023, 16:55
/report/000110465923042299-reasons-bryan-m-2023-04-03 Mallinckrodt plc 03 Apr 2023 1 $0 4 EVP & CFO 05 Apr 2023, 19:06
/report/000110465922129618-reasons-bryan-m-2022-12-14 Mallinckrodt plc 14 Dec 2022 1 $0 4 EVP & CFO 22 Dec 2022, 16:47
/report/000089924322023452-reasons-bryan-m-2022-06-16 Mallinckrodt plc 16 Jun 2022 2 $0 4 EVP & CFO 21 Jun 2022, 18:23
ACRS Aclaris Therapeutics, Inc. 02 Jun 2022 4 $0 4 Director 06 Jun 2022, 17:33
/report/000106299322013172-reasons-bryan-m-2022-05-18 Societal CDMO, Inc. 18 May 2022 2 $0 4 Director 20 May 2022, 17:36
ACRS Aclaris Therapeutics, Inc. 03 Jun 2021 2 $0 4 Director 04 Jun 2021, 20:09
/report/000119248221000430-reasons-bryan-m-2021-04-20-restatement Recro Pharma, Inc. 20 Apr 2021 1 $0 4/A Director 17 May 2021, 16:03